Clinical trials: Kidney Failure,Chronic
Anemia, End Stage Renal Disease (ESRD)
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
This study was conducted to explore a new therapy for anemia in participants with end stage renal disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or hemoglobin.
- Trial name
- Pyrenees (NCT02278341)
- Testing
- Roxadustat, Epoetin alfa, Darbepoetin alfa
- Where
- 143 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 838 people
- Sponsor
- Astellas Pharma Europe B.V.
Peritoneal Dialysis, Chronic Kidney Disease
Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis
The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal dialysis.
- Trial name
- NCT00196755
- Testing
- Sevelamer Hydrochloride (Renagel®), Calcium acetate (PhosLo® )
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 138 people
- Sponsor
- Genzyme, a Sanofi Company
Renal Insufficiency, Chronic, Chronic Kidney Disease stage3
Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.
Gemini is being evaluated in a placebo controlled, single dose, escalating dose study to evaluate the safety and tolerability of intravenous Gemini in adult subjects with stage 3 or 4 chronic kidney disease.
- Conditions
- Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
- Trial name
- PRIME (NCT06863467)
- Testing
- Intravenous Gemini
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Revelation Biosciences, Inc
Hypertension
Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease
This study is a post-marketing surveillance in Japan, and it is a local prospective, company sponsored and observational study of patient who have been treated by Adalat CR for hypertension with diabetes and/or chronic kidney…
- Trial name
- NCT01363336
- Testing
- Nifedipine (Adalat CR, BAYA1040)
- Where
- Japan
- Volunteers
- 1,882 people
- Sponsor
- Bayer
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
End Stage Renal Disease
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Randomized, controlled, parallel groups, open-label, blinded end-point assessment, multicenter study, comparing the effects of a low glucose peritoneal dialysis solution, XyloCore, to glucose solutions (Physioneal, Fixioneal…
- Trial name
- ELIXIR (NCT03994471)
- Testing
- XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght, 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution
- Where
- 41 sites in Denmark, Germany and 4 more
- Volunteers
- 170 people
- Sponsor
- Iperboreal Pharma Srl
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease
This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with chronic kidney disease.
- Trial name
- NCT03976115
- Testing
- DDO-3055
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Kidney Diseases
Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis
The purpose of this study is to evaluate the effecacy and safety of dialysis centers switching its dialysis patients from using recombinant human erythropoietin injection (CHO Cell) (ESPO) to Pegol-Sihematide injection on…
- Trial name
- NCT03902691
- Testing
- Pegol-Sihematide, ESPO
- Where
- China
- Volunteers
- 372 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetic Kidney Disease, Chronic Kidney Disease Stage 1
Prospective Decision Impact Trial of KidneyIntelX
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
- Trial name
- NCT04960514
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Immunoglobulin A Nephropathy, IgAN
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
- Trial name
- I CAN (NCT06291376)
- Testing
- Ravulizumab
- Where
- 246 sites in United States, Argentina and 26 more
- Volunteers
- 584 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Renal Failure
Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis
To evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01903213
- Testing
- bixalomer
- Where
- 8 sites in Japan
- Volunteers
- 123 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease
Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD
To assess the effects of 12 weeks of treatment with lanthanum carbonate compared with placebo on serum intact Fibroblast Growth Factor 23 (FGF23) levels.
- Trial name
- NCT01128179
- Testing
- Lanthanum carbonate
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Shire
Chronic Kidney Disease
Study of Phosphate Levels in Patients With Chronic Kidney Disease
The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.
- Trial name
- PA21 (NCT00824460)
- Testing
- 1.25 g PA21 (250 mg iron), 5.0 g PA21 (1,000 mg iron), 7.5 g PA21 (1,500 mg iron)
- Where
- 60 sites in United States, Bulgaria and 7 more
- Volunteers
- 154 people
- Sponsor
- Vifor Pharma
Stenosis, Restenosis
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
The objective of this study is to assess the safety and effectiveness of the COVERA™ Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the Arteriovenous (AV) access circuit.
- Trial name
- AVeNEW (NCT02649946)
- Testing
- Covera Vascular Covered Stent following PTA, Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon
- Where
- 24 sites in United States, Australia and 6 more
- Volunteers
- 280 people
- Sponsor
- C. R. Bard
Chronic Kidney Disease, CKD
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who…
- Conditions
- Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
- Trial name
- ARTEMIS (NCT05746559)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 18 more
- Volunteers
- 555 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
End Stage Renal Disease (ESRD)
Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)
Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD).
- Trial name
- NCT03812679
- Testing
- AMIA APD Solution Generation System
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Vantive Health LLC
Chronic Renal Failure, Chronic Kidney Disease
Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA)…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- PEARL 2 (NCT00598442)
- Testing
- peginesatide, Darbepoetin alfa
- Where
- 64 sites in United States, Bulgaria and 8 more
- Volunteers
- 493 people
- Sponsor
- Affymax
Thrombosis, Factor XI
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
An oral dose of BMS-986177 administered in End-stage Renal Dysfunction (ESRD) participants before and after a hemodialysis session to evaluate safety, tolerability, and pharmacokinetics in this patient population.
- Conditions
- Thrombosis, Factor XI, Renal Impairment, ESRD (End-Stage Renal Disease)
- Trial name
- NCT02902679
- Testing
- BMS-986177
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Bristol-Myers Squibb
Hypertension, CKD - Chronic Kidney Disease
A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease
Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of the six-channel radiofrequency（RF) renal denervation system-comprising the six-channel radiofrequency…
- Trial name
- NCT07130955
- Testing
- Six-channel RF Renal Denervation System
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Hyperparathyroidism, Secondary
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).
- Trial name
- NCT01932970
- Testing
- Etelcalcetide
- Where
- 40 sites in United States
- Volunteers
- 158 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.